Monitor for Phase 2 trial initiation details and any future clinical data readouts for atebimetinib in combination with PD-1 blockade. The SITC poster itself is unlikely to move the stock without quantitative efficacy or safety data.
Price Chart
Executive Summary
Immuneering announced a poster presentation at SITC 2026 showing that atebimetinib enhances PD-1 checkpoint blockade in RAS mutant tumor models. The preclinical data support plans for a Phase 2 study of atebimetinib in combination with PD-1 blockade in lung cancer. This is a non-clinical, non-regulatory milestone with no new financial data or catalyst date.
Key Facts
- Poster presentation at SITC 2026 (Nov 4-8, Phoenix, AZ) on atebimetinib + PD-1 blockade in RAS mutant tumors
- Preclinical data show atebimetinib enhances PD-1 checkpoint blockade in RAS mutant tumor models
- Findings support planned Phase 2 study of atebimetinib + PD-1 blockade in lung cancer patients
- No clinical data, regulatory action, or financial figures disclosed
Financial Impact
No financial impact disclosed; preclinical data only
Risk Factors
- Preclinical results may not translate to human clinical trials
- No timeline or specific trial design for the Phase 2 study provided
- Company has no approved products and relies on future funding
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3373822 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | Press Release | — | awaiting T+1 | — | — |
Oct 2, 2026 24d ago | Press Release | $4.07 $4.04 | ▼ −0.74% | ▼ −1.41% | $3.73 (−8.35%) |
Sep 28, 2026 28d ago | Press Release | $4.16 $4.13 | ▼ −0.72% | ▼ −0.54% | $3.73 (−10.34%) |
Aug 26, 2026 8w ago | Press Release | $5.21 $4.99 | ▼ −4.22% | ▼ −4.00% | $3.73 (−28.41%) |
Aug 5, 2026 11w ago | 8-K | $4.39 $4.46 | ▲ +1.59% | ▲ +1.75% | $3.73 (−15.03%) |
Aug 5, 2026 11w ago | Press Release | $4.39 $4.46 | ▲ +1.59% | ▲ +1.75% | $3.73 (−15.03%) |
Jun 11, 2026 19w ago | Institutional Cluster | $4.12 $4.19 | ▲ +1.70% | ▲ +1.16% | $3.73 (−9.47%) |
Jun 1, 2026 20w ago | 8-K | $4.28 $4.55 | ▲ +6.31% | ▲ +7.00% | $3.73 (−12.85%) |
May 15, 2026 23w ago | Press Release | $5.16 $4.87 | ▼ −5.62% | ▼ −5.56% | $3.73 (−27.71%) |
Apr 21, 2026 26w ago | Press Release | $5.89 $6.13 | ▲ +4.07% | ▲ +4.47% | $3.73 (−36.67%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers